Severe Impairment of NMDA Receptor Function in Mice Carrying Targeted Point Mutations in the Glycine Binding Site Results in Drug-Resistant Nonhabituating Hyperactivity
Open Access
- 1 August 2002
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 22 (15) , 6713-6723
- https://doi.org/10.1523/jneurosci.22-15-06713.2002
Abstract
NMDA receptor hypofunction has been implicated in the pathophysiology of schizophrenia, and pharmacological and genetic approaches have been used to model such dysfunction. We previously have described two mouse lines carrying point mutations in the NMDA receptor glycine binding site,Grin1D481N andGrin1K483Q, which exhibit 5- and 86-fold reductions in receptor glycine affinity, respectively.Grin1D481N animals exhibit a relatively mild phenotype compatible with a moderate reduction in NMDA receptor function, whereas Grin1K483Qanimals die shortly after birth. In this study we have characterized compound heterozygote Grin1D481N/K483Qmice, which are viable and exhibited biphasic NMDA receptor glycine affinities compatible with the presence of each of the two mutated alleles. Grin1D481N/K483Q mice exhibited a marked NMDA receptor hypofunction revealed by deficits in hippocampal long-term potentiation, which were rescued by the glycine site agonist d-serine, which also facilitated NMDA synaptic currents in mutant, but not in wild-type, mice. Analysis of striatal monoamine levels revealed an apparent dopaminergic and serotonergic hyperfunction. Behaviorally,Grin1D481N/K483Q mice were insensitive to acute dizocilpine pretreatment and exhibited increased startle response but normal prepulse inhibition. Most strikingly, mutant mice exhibited a sustained, nonhabituating hyperactivity and increased stereotyped behavior that were resistant to suppression by antipsychotics and the benzodiazepine site agonist Zolpidem. They also displayed a disruption of nest building behavior and were unable to perform a cued learning paradigm in the Morris water maze. We speculate that the severity of NMDA receptor hypofunction in these mice may account for their profound behavioral phenotype and insensitivity to antipsychotics.Keywords
This publication has 38 references indexed in Scilit:
- Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological functionNeuropharmacology, 2001
- Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in reviewPsychopharmacology, 2001
- Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New EvidenceAnnual Review of Pharmacology and Toxicology, 2001
- Mechanism of action of the hypnotic zolpidem in vivoBritish Journal of Pharmacology, 2000
- The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in miceJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
- Identification of Amino Acid Residues of the NR2A Subunit That Control Glutamate Potency in Recombinant NR1/NR2A NMDA ReceptorsJournal of Neuroscience, 1998
- Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypesEuropean Neuropsychopharmacology, 1996
- Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal deathPublished by Elsevier ,1994
- Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-d-aspartate receptorNeuron, 1991
- Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycineBiophysical Journal, 1991